# Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)

> **NCT04138212** · PHASE3 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 456 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Paclitaxel, Cisplatin
- **RADIATION:** neoadjuvant chemoradiation therapy

## Key facts

- **NCT ID:** NCT04138212
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-22
- **Primary completion:** 2023-12-21
- **Final completion:** 2028-12-21
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138212, "Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04138212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*